240 related articles for article (PubMed ID: 18348680)
41. Treatment of Parkinson's disease : what's on the horizon?
Wu SS; Frucht SJ
CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
[TBL] [Abstract][Full Text] [Related]
42. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
[TBL] [Abstract][Full Text] [Related]
43. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
44. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
45. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain.
Chauhan NB; Siegel GJ; Lee JM
J Chem Neuroanat; 2001 Jun; 21(4):277-88. PubMed ID: 11429269
[TBL] [Abstract][Full Text] [Related]
46. Neurotrophic Factors in Parkinson's Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Ferreira RN; de Miranda AS; Rocha NP; Simoes E Silva AC; Teixeira AL; da Silva Camargos ER
Curr Med Chem; 2018; 25(31):3682-3702. PubMed ID: 29532753
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease.
Manfredsson FP; Okun MS; Mandel RJ
Curr Gene Ther; 2009 Oct; 9(5):375-88. PubMed ID: 19860652
[TBL] [Abstract][Full Text] [Related]
48. Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined effects with glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor.
Koeberle PD; Ball AK
Neuroscience; 2002; 110(3):555-67. PubMed ID: 11906793
[TBL] [Abstract][Full Text] [Related]
49. Mutation analysis of the glial cell line-derived neurotrophic factor gene in Parkinson's disease.
Wartiovaara K; Hytönen M; Vuori M; Paulin L; Rinne J; Sariola H
Exp Neurol; 1998 Aug; 152(2):307-9. PubMed ID: 9710530
[TBL] [Abstract][Full Text] [Related]
50. Continuing trials of GDNF in Parkinson's disease.
Barker RA
Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740
[No Abstract] [Full Text] [Related]
51. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
52. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
Hegarty SV; O'Leary E; Solger F; Stanicka J; Sullivan AM; O'Keeffe GW
Neurotox Res; 2016 Oct; 30(3):510-20. PubMed ID: 27256286
[TBL] [Abstract][Full Text] [Related]
53. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
[TBL] [Abstract][Full Text] [Related]
54. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
Visanji NP; Orsi A; Johnston TH; Howson PA; Dixon K; Callizot N; Brotchie JM; Rees DD
FASEB J; 2008 Jul; 22(7):2488-97. PubMed ID: 18364399
[TBL] [Abstract][Full Text] [Related]
55. Gene transfer techniques for the delivery of GDNF in Parkinson's disease.
Ridet JL; Déglon N; Aebischer P
Novartis Found Symp; 2000; 231():202-15; discussion 215-9, 302-6. PubMed ID: 11131539
[TBL] [Abstract][Full Text] [Related]
56. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
Akerud P; Alberch J; Eketjäll S; Wagner J; Arenas E
J Neurochem; 1999 Jul; 73(1):70-8. PubMed ID: 10386956
[TBL] [Abstract][Full Text] [Related]
57. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies.
Eslamboli A
Rev Neurosci; 2005; 16(4):303-10. PubMed ID: 16519007
[TBL] [Abstract][Full Text] [Related]
58. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.
Rodrigues TM; Jerónimo-Santos A; Outeiro TF; Sebastião AM; Diógenes MJ
Drugs Aging; 2014 Apr; 31(4):239-61. PubMed ID: 24610720
[TBL] [Abstract][Full Text] [Related]
59. AAV2-neurturin (CERE-120) for Parkinson's disease.
Hickey P; Stacy M
Expert Opin Biol Ther; 2013 Jan; 13(1):137-45. PubMed ID: 23228025
[TBL] [Abstract][Full Text] [Related]
60. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
Hoban DB; Howard L; Dowd E
Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
